HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

HLA-A11

Also Known As:
HLA A11
Networked: 61 relevant articles (0 outcomes, 10 trials/studies)

Bio-Agent Context: Research Results

Experts

1. Itoh, Kyogo: 4 articles (02/2009 - 02/2004)
2. Noguchi, Masanori: 3 articles (02/2009 - 10/2005)
3. Shichijo, Shigeki: 3 articles (02/2009 - 02/2004)
4. Takedatsu, Hiroko: 3 articles (04/2007 - 02/2004)
5. Zhao, Li: 2 articles (01/2012 - 09/2005)
6. Harada, M: 2 articles (12/2007 - 08/2001)
7. Harada, Mamoru: 2 articles (04/2007 - 10/2005)
8. Matsueda, Satoko: 2 articles (04/2007 - 10/2005)
9. Bjarnadottir, Kristjana: 1 article (09/2013)
10. Gudmundsson, Sveinn: 1 article (09/2013)

Related Diseases

1. Neoplasms (Cancer)
08/31/2001 - "We demonstrated two major findings: (i) a part of chromosome 6 coding for HLA haplotypes was deleted from the genome of chondrosarcoma cell line, OUMS-27; furthermore, immunohistostaining for HLA-A11 showed that the original chondrosarcoma tissue lost the expression of HLA-A11, implicating that HLA haplotype loss was already present in the original tumor tissue and (2) HLA class I-restricted and autologous tumor-specific cytotoxic T cells (CTL) were generated from peripheral blood lymphocytes of the patient with chondrosarcoma, from whom OUMS-27 originated. "
05/15/2004 - "The results of monitoring studies indicated that T cell clones reactive with the mutated HLA-A11 gene product and the mutated p14ARF product were highly represented in the peripheral blood of patient 1913 1 wk following adoptive transfer, indicating that they may have played a role in the nearly complete tumor regression that was observed following this treatment."
11/01/2009 - "Our results demonstrate that the antigenic E6 peptides derived from HPV18 are potential candidates for the treatment of HPV 18-associated tumors in HLA-A11(+) populations."
02/01/2004 - "One RLI- or KIAA0036-derived peptide induced tumor-reactive CTLs in PBMCs of HLA-A3(+) and -A11(+) or HLA-A11(+) and -A33(+) cancer patients also with various frequencies (22-67%), respectively, whereas the other peptide induced CTL activity in only HLA-A33(+) patients. "
02/01/2009 - "These results suggest that this peptide can be applicable as a cancer vaccine not only for HLA-A24+, but also for HLA-A11+, HLA-A31+ and HLA-A33+ prostate cancer patients."
2. Skin Neoplasms (Skin Cancer)
3. Prostatic Neoplasms (Prostate Cancer)
4. Lymphoma (Lymphomas)
5. Hypertension (High Blood Pressure)

Related Drugs and Biologics

1. Antigens
2. Peptides
3. HLA-A3 Antigen (HLA A3 Antigen)
4. HLA-A31
5. HLA-A Antigens (HLA-A)
6. HLA-A33
7. HLA-B13
8. HLA Antigens (Human Leukocyte Antigens)
9. Tumor Suppressor Protein p14ARF (p14ARF)
10. HLA-DR7 Antigen (HLA DR7 Antigen)

Related Therapies and Procedures

1. Transplantation (Transplant Recipients)
2. Homologous Transplantation (Allograft)